The lab celebrated the end of Huarui’s tenure at MIT with a late summer lunch at Shy Bird in Kendall Square (not a cloud in the sky). She’ll be joining Maddy Henley at Foghorn Therapeutics, just down the road, to fight the good fight against diseases with aberrant chromatin regulation. Good luck!
The Koehler Lab aims to innovate in the earliest stages of drug discovery by building chemical tools or technologies to assist in the process of target validation and by expanding the repertoire of protein targets that are considered to be druggable. We focus primarily on building chemical tools and methods for studying temporal aspects of transcriptional regulation in development and disease with a focus on cancer.
The Koehler Lab is supported through the generosity of our public and private funding partners.
We will gladly accommodate requests for greater accessibility of public content.
